AR076175A1 - Combinaciones para el tratamiento de enfermedades respiratorias. - Google Patents

Combinaciones para el tratamiento de enfermedades respiratorias.

Info

Publication number
AR076175A1
AR076175A1 ARP100101087A ARP100101087A AR076175A1 AR 076175 A1 AR076175 A1 AR 076175A1 AR P100101087 A ARP100101087 A AR P100101087A AR P100101087 A ARP100101087 A AR P100101087A AR 076175 A1 AR076175 A1 AR 076175A1
Authority
AR
Argentina
Prior art keywords
ethyl
receptor agonist
pharmaceutical product
oxo
hydroxy
Prior art date
Application number
ARP100101087A
Other languages
English (en)
Inventor
Frank Burkamp
Hansen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR076175A1 publication Critical patent/AR076175A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente proporciona un producto farmacéutico que comprende, combinados: (1) un agonista del receptor de glucocorticoides especifico y (2) un agonista del receptor adrenérgico 2, un agonista del receptor adrenérgico 2 /antagonista del receptor M3 dual, un antagonista muscarínico, un inhibidor de la p38 cinasa, un inhibidor de la elastasa neutrofila, un inhibidor de la PDE4 fosfodiesterasa, un inhibidor de la IKK2 cinasa o un agonista del receptor de glucocorticoides no esteroide, y el uso de dicho producto en el tratamiento de enfermedades respiratorias. Reivindicacion 2: Un producto farmacéutico de acuerdo con la reivindicacion 1 caracterizado porque está en una forma adecuada para la administracion por inhalacion. Reivindicacion 5: Un producto farmacéutico caracterizado porque comprende un preparado de un primer principio activo que es furan-2-carboxilato de (1R,3aS,3bS,10aR,10bS,11S,12aS)1-{[(cianometil)sulfanil]carbonil }-7-(4-fluorofenil)-11-hidroxi-10a,12a-dimetil-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-tetradecahidrociclopenta[5,6]nafto[1,2-f]indazol-1-ilo y un preparado de un segundo principio activo seleccionado entre un agonista del receptor adrenérgico beta2, un agonista del receptor adrenérgico beta2/antagonista del receptor M3 dual, un antagonista muscarínico, un inhibidor de la p38 cinasa, un inhibidor de la elastasa neutrofila, un inhibidor de la PDE4 fosfodiesterasa, un inhibidor de la IKK2 cinasa o un agonista del receptor de glucocorticoides no esteroide en el que los preparados son para la administracion simultánea, secuencial o por separado a un paciente que los requiera. Reivindicacion 6: Un producto farmacéutico de acuerdo con la reivindicacion 5, caracterizado porque los preparados del primer y el segundo principio activo están cada uno en una forma adecuada para la administracion por inhalacion. Reivindicacion 8: Un producto farmacéutico de acuerdo con cualquiera de las reivindicaciones precedentes caracterizado porque el segundo principio activo se selecciona entre: N-[2-(Dietilamino)etil]j-N-(2-{[2-(4-hidroxi-2-oxo-2,3-dihidro-1,3-benzotiazol-7-il)etil}amino} etil)-3-(2-naftalen-1-iletoxi)propanamida, (3R)-1-[2-(4-fluorofenil)etil]-3-{[(2S)-2-fenil-2-piperidin-1-ilpropanoil]oxi}-1-azoniabiciclo[2.2.2]octano, (3R)-1-[2-oxo-2-(piridin-2-ilamino)etil]-3-{[(1-fenilcicloheptil)carbonil]oxi} -1-azoniabiciclo[2.2.2joctano, N-ciclopropil-3-fluoro-4-metil-5-{3-[(1-{2-[2-(metilamino)etoxi]fenil} ciclopropil)amino]-2-oxopirazin-1(2H)-il} benzamida, N-Ciclohexil-N-(2-{[2-(5-hidroxi-3-oxo-3,4-dihidro-2H-1,4-benzoxazin-8-il)etil]amino}etil)-3-{2-[3-(1-metil-1H-pirazol-4-il)fenil]etoxi}propanamida, N-ciclohexil-N3-[2-(3-fluorofenil)etil]-N-(2-{[2-(4-hidroxi-2-oxo-2,3-dihidro-1,3- benzotiazol-7-il)etil]amino}etil)-beta-alaninamida, o una sal farmacéuticamente aceptable de estos.
ARP100101087A 2009-04-03 2010-03-31 Combinaciones para el tratamiento de enfermedades respiratorias. AR076175A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16631009P 2009-04-03 2009-04-03

Publications (1)

Publication Number Publication Date
AR076175A1 true AR076175A1 (es) 2011-05-26

Family

ID=42828553

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101087A AR076175A1 (es) 2009-04-03 2010-03-31 Combinaciones para el tratamiento de enfermedades respiratorias.

Country Status (14)

Country Link
US (1) US20100261690A1 (es)
EP (1) EP2414376A1 (es)
JP (1) JP2012522767A (es)
KR (1) KR20120022751A (es)
CN (1) CN102803285A (es)
AR (1) AR076175A1 (es)
AU (1) AU2010231955A1 (es)
BR (1) BRPI1012726A2 (es)
CA (1) CA2756926A1 (es)
MX (1) MX2011010209A (es)
RU (1) RU2011140239A (es)
TW (1) TW201039833A (es)
UY (1) UY32521A (es)
WO (1) WO2010114472A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010003698A (es) * 2007-10-04 2010-04-21 Astrazeneca Ab Compuestos de [3,2-c]pirazol esteroides con actividad glucocorticoide.
AU2008341590A1 (en) * 2007-12-20 2009-07-02 Astrazeneca Ab Steroid derivatives acting as glucocorticosteroid receptor agonists
UY31920A (es) * 2008-06-20 2010-01-29 Astrazeneca Ab Nueva combinacion-408
UY32523A (es) * 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticosteroides
UY32525A (es) * 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticosteroides
UY32520A (es) * 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
WO2011073662A1 (en) * 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
EP2569285A1 (en) 2010-05-10 2013-03-20 Gilead Sciences, Inc. Bifunctional quinoline derivatives
US8367829B2 (en) 2010-05-10 2013-02-05 Gilead Sciences, Inc. Bi-functional pyrazolopyridine compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3129218A (en) * 1961-11-01 1964-04-14 Merck & Co Inc 2-alkoxymethylene steroids of the androstane and pregnane series
US3072639A (en) * 1962-03-05 1963-01-08 Merck & Co Inc 16-oxygenated-4-pregneno-[3, 2-c] pyrazoles and process of preparing them
US3364203A (en) * 1965-09-09 1968-01-16 Syntex Corp 6, 7-methylene and 6, 7-halomethylene pyrazole pregnanes and processes for their preparation
US3471477A (en) * 1967-10-18 1969-10-07 Syntex Corp 6-gem-difluoro (3,2-c) and (2,3-d) pyrazole steroids
DE2735110A1 (de) * 1977-08-04 1979-02-15 Hoechst Ag Corticoid-17-alkylcarbonate und verfahren zu ihrer herstellung
DE2817988A1 (de) * 1978-04-25 1979-11-08 Hoechst Ag Corticoid 17-alkylcarbonate und verfahren zu deren herstellung
SE8306370D0 (sv) * 1983-11-18 1983-11-18 Draco Ab Novel androstane-17beta-carboxylic acid esters, a process and intermediates for their preparation, compositions and method for the treatment of inflammatory conditions
EP2039700A2 (en) * 2001-04-30 2009-03-25 Glaxo Group Limited Novel anti-inflammatory androstane derivatives
WO2008103126A1 (en) * 2007-02-23 2008-08-28 Astrazeneca Ab Novel combination of compounds to be used in the treatment of airway diseases, especially chronic obstructive pulmonary disease (copd) and asthma
SE531698C2 (sv) * 2007-07-12 2009-07-07 Respiratorius Ab Nya bronkdilaterande a,b-omättade amider
MX2010003698A (es) * 2007-10-04 2010-04-21 Astrazeneca Ab Compuestos de [3,2-c]pirazol esteroides con actividad glucocorticoide.
UY32523A (es) * 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticosteroides
UY32520A (es) * 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides

Also Published As

Publication number Publication date
CA2756926A1 (en) 2010-10-07
KR20120022751A (ko) 2012-03-12
WO2010114472A1 (en) 2010-10-07
BRPI1012726A2 (pt) 2016-04-05
US20100261690A1 (en) 2010-10-14
TW201039833A (en) 2010-11-16
AU2010231955A1 (en) 2011-10-20
MX2011010209A (es) 2011-10-10
CN102803285A (zh) 2012-11-28
RU2011140239A (ru) 2013-05-10
JP2012522767A (ja) 2012-09-27
UY32521A (es) 2010-10-29
EP2414376A1 (en) 2012-02-08

Similar Documents

Publication Publication Date Title
AR076175A1 (es) Combinaciones para el tratamiento de enfermedades respiratorias.
JP5386173B2 (ja) 閉経前の性的欲求障害の治療のためのフリバンセリンの使用
US8481001B2 (en) Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer
CA3025080A1 (en) Cannabis compositions and methods
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
JP2009541443A5 (es)
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
BRPI0507609A (pt) combinações terapêuticas de anti-psicóticos atìpicos com antagonistas de fator de liberação de corticotropina
MY167423A (en) Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use
CN104994854A (zh) 通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法
ES2602973T3 (es) Combinaciones de agonistas del receptor de serotonina para el tratamiento de trastornos del movimiento
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
JP2011508765A5 (es)
JP2015536973A (ja) ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物
NZ605888A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
JP2015524444A5 (es)
BR112015029401A2 (pt) derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
UA102885C2 (ru) Таблетка для орального введения, которая содержит тамсулозин и солифенацин
MX2009008363A (es) Combinacion de un antagonista de receptor muscarinico y un agonista de receptor adrenergico beta 2.
TW202128169A (zh) 具有降低副作用之hdac治療劑量
ES2840079T3 (es) Composición farmacéutica para el tratamiento de la esteatosis hepática no alcohólica
JP2024511973A (ja) Ｃｎｓ疾患および全身性疾患を治療するためのｌｉｎｅ－１阻害剤
JP6563998B2 (ja) 治療計画
BR112012020377A2 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
CA2991276A1 (en) Pharmaceutical combinations and their use

Legal Events

Date Code Title Description
FB Suspension of granting procedure